Pharmaceutical dosage form for oral administration of an inhibitor of the Bcl-2 family

摘要

A pharmaceutical dosage form comprising a solid dispersion product comprising a pharmaceutically active ingredient, at least one pharmaceutically acceptable polymer comprising a homopolymer or a copolymer of N-vinylpyrrolidone, and at least one pharmaceutically acceptable solubilizer comprising a tocopheryl compound having a polyalkylene glycol radical, said pharmaceutically active ingredient being N- (4- (4 - ((2- (4-chlorophenyl) -5,5-dimethyl-1-cyclohex-1-en-1-yl) methyl)) piperazin-1-yl) benzoyl) -4- (((1R) -3- (morpholin-4-yl) -1 - ((phenylsulfanyl) methyl) propyl) amino) -3 - ((trifluoromethyl) sulfonyl) benzenesulfonamide, a salt, or a hydrate thereof.